Search tips
Search criteria 


Logo of bmjThe BMJ
BMJ. 1994 April 2; 308(6933): 879–883.
PMCID: PMC2539871

Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial.


OBJECTIVE--To assess the efficacy of tacrine and lecithin in treating Alzheimer's disease over nine months. DESIGN--Double blind randomised controlled trial. SETTING--Outpatients clinic of university department of geriatric medicine. SUBJECTS--53 subjects (26 women, 27 men) with probable Alzheimer's disease. 41 completed the dose finding phase and were randomised to treatment. 32 (14 tacrine, 18 placebo) completed nine months' treatment. INTERVENTIONS--Lecithin and tacrine or lecithin and placebo for 36 weeks. MAIN OUTCOME MEASURES--Scores on neuropsychological tests sensitive to deficits in the cholinergic system; mini-mental state score; behaviour change; mood; functional state; and stress in carers. RESULTS--The tacrine and placebo groups were similar except that the tacrine group had a longer duration of disease (mean 5.4 v 2.5 years in placebo group; P = 0.003). Only 17 of the 32 patients could tolerate the maximum dose of tacrine (100 mg). No significant difference was found between the groups for any of the tests after nine months' treatment except for the digit backwards test, which is insensitive to cholinergic deficit. Analysis of subjects taking the maximum dose of tacrine and of subjects with mild dementia also found no differences. CONCLUSIONS--Tacrine produces no clinically relevant improvement over 36 weeks at the doses tolerated by these patients.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Hollander E, Mohs RC, Davis KL. Cholinergic approaches to the treatment of Alzheimer's disease. Br Med Bull. 1986 Jan;42(1):97–100. [PubMed]
  • Bartus RT, Dean RL, 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982 Jul 30;217(4558):408–414. [PubMed]
  • Bruno G, Mohr E, Gillespie M, Fedio P, Chase TN. Muscarinic agonist therapy of Alzheimer's disease. A clinical trial of RS-86. Arch Neurol. 1986 Jul;43(7):659–661. [PubMed]
  • Mouradian MM, Mohr E, Williams JA, Chase TN. No response to high-dose muscarinic agonist therapy in Alzheimer's disease. Neurology. 1988 Apr;38(4):606–608. [PubMed]
  • Tariot PN, Cohen RM, Welkowitz JA, Sunderland T, Newhouse PA, Murphy DL, Weingartner H. Multiple-dose arecoline infusions in Alzheimer's disease. Arch Gen Psychiatry. 1988 Oct;45(10):901–905. [PubMed]
  • Penn RD, Martin EM, Wilson RS, Fox JH, Savoy SM. Intraventricular bethanechol infusion for Alzheimer's disease: results of double-blind and escalating-dose trials. Neurology. 1988 Feb;38(2):219–222. [PubMed]
  • Little A, Levy R, Chuaqui-Kidd P, Hand D. A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1985 Aug;48(8):736–742. [PMC free article] [PubMed]
  • Jorm AF. Effects of cholinergic enhancement therapies on memory function in Alzheimer's disease: a meta-analysis of the literature. Aust N Z J Psychiatry. 1986 Jun;20(2):237–240. [PubMed]
  • Davis KL, Mohs RC. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry. 1982 Nov;139(11):1421–1424. [PubMed]
  • Stern Y, Sano M, Mayeux R. Long-term administration of oral physostigmine in Alzheimer's disease. Neurology. 1988 Dec;38(12):1837–1841. [PubMed]
  • Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med. 1986 Nov 13;315(20):1241–1245. [PubMed]
  • Tacrine as a treatment for Alzheimer's disease: editor's note. An interim report from the FDA. A response from Summers et al. N Engl J Med. 1991 Jan 31;324(5):349–352. [PubMed]
  • Oral tetrahydroaminoacridine in the treatment of senile dementia, Alzheimer's type. N Engl J Med. 1987 Jun 18;316(25):1603–1605. [PubMed]
  • Hayward L, Brodaty H. THA and Alzheimer's disease. Aust N Z J Psychiatry. 1987 Dec;21(4):618–619. [PubMed]
  • Cholinergic treatment in Alzheimer's disease: encouraging results. Lancet. 1987 Jan 17;1(8525):139–141. [PubMed]
  • Eagger SA, Levy R, Sahakian BJ. Tacrine in Alzheimer's disease. Lancet. 1991 Apr 27;337(8748):989–992. [PubMed]
  • Molloy DW, Guyatt GH, Wilson DB, Duke R, Rees L, Singer J. Effect of tetrahydroaminoacridine on cognition, function and behaviour in Alzheimer's disease. CMAJ. 1991 Jan 1;144(1):29–34. [PMC free article] [PubMed]
  • Kaye WH, Sitaram N, Weingartner H, Ebert MH, Smallberg S, Gillin JC. Modest facilitation on memory in dementia with combined lecithin and anticholinerestase treatment. Biol Psychiatry. 1982 Feb;17(2):275–280. [PubMed]
  • Fitten LJ, Perryman KM, Gross PL, Fine H, Cummins J, Marshall C. Treatment of Alzheimer's disease with short- and long-term oral THA and lecithin: a double-blind study. Am J Psychiatry. 1990 Feb;147(2):239–242. [PubMed]
  • Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, Schneider LS, Whitehouse PJ, Hoover TM, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med. 1992 Oct 29;327(18):1253–1259. [PubMed]
  • Chatellier G, Lacomblez L. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine. BMJ. 1990 Feb 24;300(6723):495–499. [PMC free article] [PubMed]
  • McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul;34(7):939–944. [PubMed]
  • Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology. 1974 Nov;24(11):1019–1025. [PubMed]
  • Muramoto O. Selective reminding in normal and demented aged people: auditory verbal versus visual spatial task. Cortex. 1984 Dec;20(4):461–478. [PubMed]
  • Christensen H, Maltby N, Jorm AF, Creasey H, Broe GA. Cholinergic 'blockade' as a model of the cognitive deficits in Alzheimer's disease. Brain. 1992 Dec;115(Pt 6):1681–1699. [PubMed]
  • Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189–198. [PubMed]
  • Hersch EL, Kral VA, Palmer RB. Clinical value of the London Psychogeriatric Rating Scale. J Am Geriatr Soc. 1978 Aug;26(8):348–354. [PubMed]
  • Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969 Autumn;9(3):179–186. [PubMed]
  • Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17(1):37–49. [PubMed]
  • Beller SA, Overall JE, Rhoades HM, Swann AC. Long-term outpatient treatment of senile dementia with oral physostigmine. J Clin Psychiatry. 1988 Oct;49(10):400–404. [PubMed]
  • Peters BH, Levin HS. Effects of physostigmine and lecithin on memory in Alzheimer disease. Ann Neurol. 1979 Sep;6(3):219–221. [PubMed]
  • Applegate WB, Blass JP, Williams TF. Instruments for the functional assessment of older patients. N Engl J Med. 1990 Apr 26;322(17):1207–1214. [PubMed]
  • Wilcock GK, Surmon DJ, Scott M, Boyle M, Mulligan K, Neubauer KA, O'Neill D, Royston VH. An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease. Age Ageing. 1993 Sep;22(5):316–324. [PubMed]
  • Gauthier S, Bouchard R, Lamontagne A, Bailey P, Bergman H, Ratner J, Tesfaye Y, Saint-Martin M, Bacher Y, Carrier L, et al. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study. N Engl J Med. 1990 May 3;322(18):1272–1276. [PubMed]
  • Hammel P, Larrey D, Bernuau J, Kalafat M, Fréneaux E, Babany G, Degott C, Feldmann G, Pessayre D, Benhamou JP. Acute hepatitis after tetrahydroaminoacridine administration for Alzheimer's disease. J Clin Gastroenterol. 1990 Jun;12(3):329–331. [PubMed]

Articles from The BMJ are provided here courtesy of BMJ Publishing Group